X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1023) 1023
Publication (87) 87
Patent (6) 6
Book Review (5) 5
Book Chapter (3) 3
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (494) 494
cardiac & cardiovascular systems (431) 431
male (330) 330
female (324) 324
index medicus (317) 317
middle aged (278) 278
aged (246) 246
treatment outcome (158) 158
acute coronary syndromes (146) 146
percutaneous coronary intervention (144) 144
heart attacks (143) 143
abridged index medicus (136) 136
risk factors (131) 131
myocardial infarction (129) 129
clopidogrel (128) 128
mortality (118) 118
platelet aggregation inhibitors - therapeutic use (108) 108
cardiovascular (105) 105
peripheral vascular disease (101) 101
aspirin (98) 98
myocardial-infarction (94) 94
prospective studies (92) 92
stents (92) 92
myocardial infarction - therapy (91) 91
ticlopidine - analogs & derivatives (91) 91
acute myocardial-infarction (86) 86
drug therapy (86) 86
angioplasty (84) 84
medicine, general & internal (83) 83
myocardial infarction - drug therapy (79) 79
thrombosis (77) 77
intervention (76) 76
time factors (76) 76
electrocardiography (73) 73
angioplasty, balloon, coronary (72) 72
care and treatment (71) 71
adult (70) 70
cardiology (70) 70
myocardial infarction - mortality (68) 68
coronary heart disease (67) 67
cardiac patients (66) 66
hemorrhage - chemically induced (66) 66
outcomes (66) 66
platelet aggregation inhibitors - administration & dosage (66) 66
antiplatelet therapy (65) 65
cardiovascular disease (65) 65
double-blind method (63) 63
acute coronary syndrome (62) 62
risk (62) 62
follow-up studies (61) 61
unfractionated heparin (61) 61
platelet aggregation inhibitors - adverse effects (59) 59
prasugrel (59) 59
heart attack (58) 58
risk assessment (58) 58
aged, 80 and over (57) 57
anticoagulants (56) 56
coronary vessels (56) 56
stroke (56) 56
therapy (56) 56
drug therapy, combination (55) 55
hematology (54) 54
internal medicine (54) 54
unstable angina (54) 54
life sciences (53) 53
trial (53) 53
anticoagulants - therapeutic use (51) 51
patients (51) 51
ticlopidine - therapeutic use (51) 51
acute coronary syndrome - drug therapy (49) 49
cardiology and cardiovascular medicine (48) 48
management (47) 47
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (46) 46
transluminal angioplasty (44) 44
abciximab (43) 43
acute coronary syndrome - therapy (43) 43
studies (43) 43
ticagrelor (43) 43
blood platelets (42) 42
clinical trials (42) 42
coronary angiography (42) 42
task-force (42) 42
ticlopidine - administration & dosage (41) 41
analysis (40) 40
angioplasty, balloon, coronary - adverse effects (40) 40
coronary artery disease (40) 40
human health and pathology (40) 40
myocardial infarction - diagnosis (40) 40
prognosis (40) 40
primary angioplasty (39) 39
registries (39) 39
bleeding (38) 38
drug-eluting stents (38) 38
metaanalysis (38) 38
patient outcomes (38) 38
guidelines (37) 37
research (37) 37
aspirin - therapeutic use (36) 36
clinical-outcomes (36) 36
disease (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (834) 834
French (195) 195
Polish (3) 3
Spanish (3) 3
German (1) 1
Japanese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 18, pp. 1713 - 1722
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2006, Volume 354, Issue 16, pp. 1706 - 1717
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2097 - 2107
Among patients who had had an acute coronary syndrome, the risk of death from coronary heart disease, nonfatal myocardial infarction, stroke, or unstable... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | MYOCARDIAL-INFARCTION | TASK-FORCE | EFFICACY | SAFETY | LDL | REDUCING LIPIDS | PCSK9 | MONOCLONAL-ANTIBODY | ASSOCIATION | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Acute Coronary Syndrome - complications | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Cardiovascular Diseases - epidemiology | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Acute coronary syndrome | Diagnosis | Myocardial infarction | Fees & charges | Lipoproteins (low density) | Heart attacks | Lipids | Cardiovascular disease | Angina | Apolipoprotein B | Ischemia | Heart diseases | Drug dosages | Statins | Cerebral infarction | Stroke | Subtilisin | Angina pectoris | Patients | Low density lipoprotein | Coronary artery disease | Cholesterol | Kexin | Monoclonal antibodies | Full text | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Pharmaceuticals | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Life Sciences | Human health and pathology
Journal Article